In patients with NSTE-ACS and high-risk features (eg, elevated troponin) treated with UFH and ad- equately pretreated with clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tirofi- ban) at the time of PCI.195,383,384 (Level of Evidence: B) 4. After PCI, it is reasonable to use 81 mg per day of aspirin in preference to higher maintenance dos- (Level of Evidence: B) 5. If the risk of morbidity from bleeding outweighs the anticipated benefit of a recommended duration of inhibitor therapy after stent implantation, ear- lier discontinuation (eg, <12 months) of P2Y12 inhibi- tor therapy is reasonable.330 (Level of Evidence: C) Class IIb 1. Continuation of DAPT beyond 12 months may be considered in patients undergoing stent implanta- tion. (Level of Evidence: C) Class III: Harm 1. 